Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.
The data gathered from these animal experiments, together with the results of other Factor 5A studies, will be reviewed to determine its sufficiency for submission of a protocol to Mayo Clinic for human studies and to FDA for an investigational new drug application.